The daily treatment with either microbiome-targeted therapies or herbal rosavin modulated the expression of hepatic mRNA signatures by ameliorating the signaling pathways contributing to NASH progression including Hippo signaling, TGF-β signaling, TNF signaling, and apoptosis. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.